Skip to main content
Top
Published in: Japanese Journal of Ophthalmology 1/2020

01-01-2020 | Blepharospasm | Clinical Investigation

Characteristics of tear abnormalities associated with benign essential blepharospasm and amelioration by means of botulinum toxin type A treatment

Authors: Yuka Hosotani, Norihiko Yokoi, Mana Okamoto, Hiroto Ishikawa, Aoi Komuro, Hiroaki Kato, Osamu Mimura, Fumi Gomi

Published in: Japanese Journal of Ophthalmology | Issue 1/2020

Login to get access

Abstract

Purpose

To investigate the characteristics of tear abnormalities with benign essential blepharospasm (BEB) and the effect of botulinum toxin type A (BTX-A) treatment.

Study Design

Prospective and clinical study.

Methods

Forty eyes of 40 patients (12 men and 28 women, ages 63.5 ±12.9) with BEB and tear abnormalities were enrolled.

Results

The average scores for subjective symptoms as evaluated by the visual analog scale (VAS) were 46.3 and Dry Eye-Related Quality-of-Life Score (DEQS) were 63.7. The fluorescein breakup time (FBUT) was 2.7 ± 1.6 sec. Among fluorescein breakup patterns (FBUPs), dimple break, with the corresponding mechanism of decreased wettability was the most frequent, observed in 29 eyes (73%). The NEI score was 0.4 ± 0.7 and the van Bijesterveld score was 0.6 ± 0.8; the Schirmer 1 test value was 13.1 ± 9.4 mm. Eighteen patients received BTX-A treatment, and significant improvement was found in severity of subjective symptoms both on VAS and DEQS as well as for FBUT. The main FBUPs changed from dimple break to random break.

Conclusion

Tear abnormalities seen in BEB correspond to short BUT-type dry eye (DE), subclassified into decreased wettability DE in view of FBUPs.
Literature
1.
go back to reference Lu R, Huang R, Li K, Zhang X, Yang H, Quan Y, et al. The influence of benign essential blepharospasm on dry eye disease and ocular inflammation. Am J Ophthalmol. 2014;157:591–7.CrossRef Lu R, Huang R, Li K, Zhang X, Yang H, Quan Y, et al. The influence of benign essential blepharospasm on dry eye disease and ocular inflammation. Am J Ophthalmol. 2014;157:591–7.CrossRef
2.
go back to reference Grandas F, Elston J, Quinn N, Marsden CD. Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry. 1988;51:767–72.CrossRef Grandas F, Elston J, Quinn N, Marsden CD. Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry. 1988;51:767–72.CrossRef
3.
go back to reference Defazio G, Livrea P. Primary blepharospasm: diagnosis and management. Drugs. 2004;64:237–44.CrossRef Defazio G, Livrea P. Primary blepharospasm: diagnosis and management. Drugs. 2004;64:237–44.CrossRef
4.
go back to reference Anderson RL, Patel BC, Holds JB, Jordan DR. Blepharospasm: past, present, and future. Ophthal Plast Reconstr Surg. 1998;14:305–17.CrossRef Anderson RL, Patel BC, Holds JB, Jordan DR. Blepharospasm: past, present, and future. Ophthal Plast Reconstr Surg. 1998;14:305–17.CrossRef
5.
go back to reference Tsubota K, Fujihara T, Kaido M, Mori A, Mimura M, Kato M. Dry eye and Meige’s syndrome. Br J Ophthalmol. 1997;81:439–42.CrossRef Tsubota K, Fujihara T, Kaido M, Mori A, Mimura M, Kato M. Dry eye and Meige’s syndrome. Br J Ophthalmol. 1997;81:439–42.CrossRef
6.
go back to reference Wakakura M, Inoue J. Application of new Japanese version of diagnostic criteria for dry eye to essential blepharospasm. Rinsho Ganka. 2008;62:857–60 (in Japanese). Wakakura M, Inoue J. Application of new Japanese version of diagnostic criteria for dry eye to essential blepharospasm. Rinsho Ganka. 2008;62:857–60 (in Japanese).
7.
go back to reference Park DI, Shin HM, Lee SY, Lew H. Tear production and drainage after botulinum toxin A injection in patients with essential blepharospasm. Acta Ophthalmol. 2013;91:e108–12.CrossRef Park DI, Shin HM, Lee SY, Lew H. Tear production and drainage after botulinum toxin A injection in patients with essential blepharospasm. Acta Ophthalmol. 2013;91:e108–12.CrossRef
8.
go back to reference Tsubota K, Yokoi N, Shimazaki J, Watanabe H, Dogru M, Yamada M, et al. New perspectives on dry eye definition and diagnosis: a consensus report by the Asia Dry Eye Society. Ocul Surf. 2017;15:65–76.CrossRef Tsubota K, Yokoi N, Shimazaki J, Watanabe H, Dogru M, Yamada M, et al. New perspectives on dry eye definition and diagnosis: a consensus report by the Asia Dry Eye Society. Ocul Surf. 2017;15:65–76.CrossRef
9.
go back to reference Toda I, Fujishima H, Tsubota K. Ocular fatigue is the major symptom of dry eye. Acta Ophthalmol (Copenh). 1993;71:347–52.CrossRef Toda I, Fujishima H, Tsubota K. Ocular fatigue is the major symptom of dry eye. Acta Ophthalmol (Copenh). 1993;71:347–52.CrossRef
10.
go back to reference Koh S, Maeda N, Hori Y, Inoue T, Watanabe H, Hirohara Y, et al. Effects of suppression of blinking on quality of vision in borderline cases of evaporative dry eye. Cornea. 2008;27:275–8.CrossRef Koh S, Maeda N, Hori Y, Inoue T, Watanabe H, Hirohara Y, et al. Effects of suppression of blinking on quality of vision in borderline cases of evaporative dry eye. Cornea. 2008;27:275–8.CrossRef
11.
go back to reference Shimazaki-Den S, Iseda H, Dogru M, Shimazaki J. Effects of diquafosol sodium eye drops on tear film stability in short BUT type of dry eye. Cornea. 2013;32:1120–5.CrossRef Shimazaki-Den S, Iseda H, Dogru M, Shimazaki J. Effects of diquafosol sodium eye drops on tear film stability in short BUT type of dry eye. Cornea. 2013;32:1120–5.CrossRef
12.
go back to reference Koh S. Clinical utility of 3% diquafosol ophthalmic solution in the treatment of dry eyes. Clin Ophthalmol. (Auckl., NZ). 2015;9:865–72.CrossRef Koh S. Clinical utility of 3% diquafosol ophthalmic solution in the treatment of dry eyes. Clin Ophthalmol. (Auckl., NZ). 2015;9:865–72.CrossRef
13.
go back to reference Yokoi N, Georgiev GA. Tear film-oriented diagnosis and tear film-oriented therapy for dry eye based on tear film dynamics. Investig Ophthalmol Vis Sci. 2018;59:Des13–des22.CrossRef Yokoi N, Georgiev GA. Tear film-oriented diagnosis and tear film-oriented therapy for dry eye based on tear film dynamics. Investig Ophthalmol Vis Sci. 2018;59:Des13–des22.CrossRef
14.
go back to reference Yokoi N, Georgiev GA. Tear-film-oriented diagnosis for dry eye. Jpn J Ophthalmol. 2019;63:127–36.CrossRef Yokoi N, Georgiev GA. Tear-film-oriented diagnosis for dry eye. Jpn J Ophthalmol. 2019;63:127–36.CrossRef
15.
go back to reference Yokoi N, Georgiev GA, Kato H, Komuro A, Sonomura Y, Sotozono C, et al. Classification of fluorescein breakup patterns: a novel method of differential diagnosis for dry eye. Am J Ophthalmol. 2017;180:72–85.CrossRef Yokoi N, Georgiev GA, Kato H, Komuro A, Sonomura Y, Sotozono C, et al. Classification of fluorescein breakup patterns: a novel method of differential diagnosis for dry eye. Am J Ophthalmol. 2017;180:72–85.CrossRef
16.
go back to reference Yokoi N, Kato H, Kinoshita S. The increase of aqueous tear volume by diquafosol sodium in dry-eye patients with Sjogren’s syndrome: a pilot study. Eye (Lond, Engl). 2016;30:857–64.CrossRef Yokoi N, Kato H, Kinoshita S. The increase of aqueous tear volume by diquafosol sodium in dry-eye patients with Sjogren’s syndrome: a pilot study. Eye (Lond, Engl). 2016;30:857–64.CrossRef
17.
go back to reference Sakane Y, Yamaguchi M, Yokoi N, Uchino M, Dogru M, Oishi T, et al. Development and validation of the Dry Eye-Related Quality-of-Life Score questionnaire. JAMA Ophthalmol. 2013;131:1331–8.CrossRef Sakane Y, Yamaguchi M, Yokoi N, Uchino M, Dogru M, Oishi T, et al. Development and validation of the Dry Eye-Related Quality-of-Life Score questionnaire. JAMA Ophthalmol. 2013;131:1331–8.CrossRef
18.
go back to reference Koh S, Watanabe H, Hosohata J, Hori Y, Hibino S, Nishida K, et al. Diagnosing dry eye using a blue-free barrier filter. Am J Ophthalmol. 2003;136:513–9.CrossRef Koh S, Watanabe H, Hosohata J, Hori Y, Hibino S, Nishida K, et al. Diagnosing dry eye using a blue-free barrier filter. Am J Ophthalmol. 2003;136:513–9.CrossRef
19.
go back to reference Lemp MA. Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. CLAO J. 1995;21:221–32.PubMed Lemp MA. Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. CLAO J. 1995;21:221–32.PubMed
20.
go back to reference van Bijsterveld OP. Diagnostic tests in the Sicca syndrome. Arch Ophthalmol. (Chic Ill : 1960). 1969;82:10–4.CrossRef van Bijsterveld OP. Diagnostic tests in the Sicca syndrome. Arch Ophthalmol. (Chic Ill : 1960). 1969;82:10–4.CrossRef
21.
go back to reference Guideline of clinical practice for blepharospasm. Nippon Ganka Gakkai zasshi. 2011;115:617–28. (in Japanese). Guideline of clinical practice for blepharospasm. Nippon Ganka Gakkai zasshi. 2011;115:617–28. (in Japanese).
22.
go back to reference Jankovic J, Havins WE, Wilkins RB. Blinking and blepharospasm. Mechanism, diagnosis, and management. JAMA. 1982;248:3160–4.CrossRef Jankovic J, Havins WE, Wilkins RB. Blinking and blepharospasm. Mechanism, diagnosis, and management. JAMA. 1982;248:3160–4.CrossRef
23.
go back to reference Yokoi N, Uchino M, Uchino Y, Dogru M, Kawashima M, Komuro A, et al. Importance of tear film instability in dry eye disease in office workers using visual display terminals: the Osaka study. Am J Ophthalmol. 2015;159:748–54.CrossRef Yokoi N, Uchino M, Uchino Y, Dogru M, Kawashima M, Komuro A, et al. Importance of tear film instability in dry eye disease in office workers using visual display terminals: the Osaka study. Am J Ophthalmol. 2015;159:748–54.CrossRef
24.
go back to reference Shimazaki J, Tsubota K, Kinoshita S, Oohashi Y, Shimomura Y, Tagawa Y, et al. Definition and diagnosis of dry eye 2006. Atarashii Ganka. 2007;24:181–4 (in Japanese). Shimazaki J, Tsubota K, Kinoshita S, Oohashi Y, Shimomura Y, Tagawa Y, et al. Definition and diagnosis of dry eye 2006. Atarashii Ganka. 2007;24:181–4 (in Japanese).
26.
go back to reference Bedarf JR, Kebir S, Michelis JP, Wabbels B, Paus S. Depression in blepharospasm: a question of facial feedback? Neuropsychiatr Dis Treat. 2017;13:1861–5.CrossRef Bedarf JR, Kebir S, Michelis JP, Wabbels B, Paus S. Depression in blepharospasm: a question of facial feedback? Neuropsychiatr Dis Treat. 2017;13:1861–5.CrossRef
27.
go back to reference Evinger C, Bao JB, Powers AS, Kassem IS, Schicatano EJ, Henriquez VM, et al. Dry eye, blinking, and blepharospasm. Mov Disord. 2002;17(Suppl 2):S75–8.CrossRef Evinger C, Bao JB, Powers AS, Kassem IS, Schicatano EJ, Henriquez VM, et al. Dry eye, blinking, and blepharospasm. Mov Disord. 2002;17(Suppl 2):S75–8.CrossRef
28.
go back to reference Argueso P, Spurr-Michaud S, Russo CL, Tisdale A, Gipson IK. MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope. Investig Ophthalmol Vis Sci. 2003;44:2487–95.CrossRef Argueso P, Spurr-Michaud S, Russo CL, Tisdale A, Gipson IK. MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope. Investig Ophthalmol Vis Sci. 2003;44:2487–95.CrossRef
30.
go back to reference Guidelines for clinical practice for dry eye. Nippon Ganka Gakkai Zasshi. 2019;123:489–592 (in Japanese). Guidelines for clinical practice for dry eye. Nippon Ganka Gakkai Zasshi. 2019;123:489–592 (in Japanese).
31.
go back to reference Knop E, Korb DR, Blackie CA, Knop N. The lid margin is an underestimated structure for preservation of ocular surface health and development of dry eye disease. Dev Ophthalmol. 2010;45:108–22.CrossRef Knop E, Korb DR, Blackie CA, Knop N. The lid margin is an underestimated structure for preservation of ocular surface health and development of dry eye disease. Dev Ophthalmol. 2010;45:108–22.CrossRef
32.
go back to reference Snir M, Weinberger D, Bourla D, Kristal-Shalit O, Dotan G, Axer-Siegel R. Quantitative changes in botulinum toxin a treatment over time in patients with essential blepharospasm and idiopathic hemifacial spasm. Am J Ophthalmol. 2003;136:99–105.CrossRef Snir M, Weinberger D, Bourla D, Kristal-Shalit O, Dotan G, Axer-Siegel R. Quantitative changes in botulinum toxin a treatment over time in patients with essential blepharospasm and idiopathic hemifacial spasm. Am J Ophthalmol. 2003;136:99–105.CrossRef
33.
go back to reference Ababneh OH, Cetinkaya A, Kulwin DR. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm. Clin Exp Ophthalmol. 2014;42:254–61.CrossRef Ababneh OH, Cetinkaya A, Kulwin DR. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm. Clin Exp Ophthalmol. 2014;42:254–61.CrossRef
34.
go back to reference Gunes A, Demirci S, Koyuncuoglu HR, Tok L, Tok O. Corneal and tear film changes after botulinum toxin-A in blepharospasm or hemifacial spasm. Cornea. 2015;34:906–10.CrossRef Gunes A, Demirci S, Koyuncuoglu HR, Tok L, Tok O. Corneal and tear film changes after botulinum toxin-A in blepharospasm or hemifacial spasm. Cornea. 2015;34:906–10.CrossRef
35.
go back to reference Kocabeyoglu S, Sekeroglu HT, Mocan MC, Muz E, Irkec M, Sanac AS. Ocular surface alterations in blepharospasm patients treated with botulinum toxin A injection. Eur J Ophthalmol. 2014;24:830–4.CrossRef Kocabeyoglu S, Sekeroglu HT, Mocan MC, Muz E, Irkec M, Sanac AS. Ocular surface alterations in blepharospasm patients treated with botulinum toxin A injection. Eur J Ophthalmol. 2014;24:830–4.CrossRef
36.
go back to reference Sahlin S, Chen E, Kaugesaar T, Almqvist H, Kjellberg K, Lennerstrand G. Effect of eyelid botulinum toxin injection on lacrimal drainage. Am J Ophthalmol. 2000;129:481–6.CrossRef Sahlin S, Chen E, Kaugesaar T, Almqvist H, Kjellberg K, Lennerstrand G. Effect of eyelid botulinum toxin injection on lacrimal drainage. Am J Ophthalmol. 2000;129:481–6.CrossRef
37.
go back to reference Ho RW, Fang PC, Chao TL, Chien CC, Kuo MT. Increase lipid tear thickness after botulinum neurotoxin A injection in patients with blepharospasm and hemifacial spasm. Sci Rep. 2018;8:8367.CrossRef Ho RW, Fang PC, Chao TL, Chien CC, Kuo MT. Increase lipid tear thickness after botulinum neurotoxin A injection in patients with blepharospasm and hemifacial spasm. Sci Rep. 2018;8:8367.CrossRef
38.
go back to reference Isshiki Y, Ishikawa H, Mimura O. Changes in ocular higher-order aberrations following botulinum toxin treatment in patients with blepharospasm : BTX improves dry eye in patients with BEB. Jpn J Ophthalmol. 2016;60:486–91.CrossRef Isshiki Y, Ishikawa H, Mimura O. Changes in ocular higher-order aberrations following botulinum toxin treatment in patients with blepharospasm : BTX improves dry eye in patients with BEB. Jpn J Ophthalmol. 2016;60:486–91.CrossRef
Metadata
Title
Characteristics of tear abnormalities associated with benign essential blepharospasm and amelioration by means of botulinum toxin type A treatment
Authors
Yuka Hosotani
Norihiko Yokoi
Mana Okamoto
Hiroto Ishikawa
Aoi Komuro
Hiroaki Kato
Osamu Mimura
Fumi Gomi
Publication date
01-01-2020
Publisher
Springer Japan
Published in
Japanese Journal of Ophthalmology / Issue 1/2020
Print ISSN: 0021-5155
Electronic ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-019-00705-3

Other articles of this Issue 1/2020

Japanese Journal of Ophthalmology 1/2020 Go to the issue